

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Keith E. Langley and Thomas C. Boone)
)
Serial No.: 08/397,320) Group Art Unit: 1813
)
Filed: March 2, 1995) Examiner: L. Scheiner
)
For: METALLOPROTEINASE INHIBITOR)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$240.00 as specified by Section 1.17(p).

Copies of the listed documents are attached.

In lieu of a statement of relevance or translation of the non-English documents, an English language version of a search report from the Patent Office in a corresponding application citing these documents and setting forth the relevance thereof is enclosed. Specifically, Japanese patent application no. JP-A-63210665 is

thereof is enclosed. Specifically, Japanese patent application no. JP-A-63210665 is cited in an enclosed office action by the Canadian Patent Office in the corresponding Canadian application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any other fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

M. Paul Barker, Esq.
Reg. No. 32,013

Date: April 9, 1998

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
BANCORP RESEARCH PARK
700 HANSEN WAY
PALO ALTO, CALIF. 94304
650-849-6600

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Atty. Docket No. 06843.0009.07000	Serial No. 08/397,320					
Applicant Keith E. Langley and Thomas C. Boone						
Filing Date March 2, 1995	Group 1813					
U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS						
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	WO A 86/04608	08/14/86	PCT			
	EP A 0188312	07/23/86	EPO			
	JP A 63-210665	09/01/88	JAPAN			
	WO A 90/11287	10/04/90	PCT			
	EP A 0404750	12/27/90	EPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Suggs et al., "Use Of Synthetic Oligonucleotides As Hybridization Probes: Isolation Of Cloned cDNA Sequences For Human β_2 -microglobulin," <u>PNAS</u> 78: 6613-6617 (1981).					
	Young et al., "Efficient Isolation Of Genes By Using Antibody Probes," <u>PNAS</u> 80: 1194-1198 (1983).					
	Goldberg et al., "Human 72-kilodalton Type IV Collagenase Forms A Complex With A Tissue Inhibitor of Metalloproteases Designated TIMP-2," <u>PNAS</u> 86: 8207-8211 (1989).					
Examiner			Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						
Form PTO 1449			Patent and Trademark Office - U.S. Department of Commerce			